
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

Harvard Bioscience, Inc.

(Name of Issuer)

Common Stock, par value \$0.01

(Title of Class of Securities)

416906105

(CUSIP Number)

July 9, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Name of Reporting Person

Paul J. Solit

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

USA

NUMBER OF	5. SOLE VOTING POWER	2,162,870 (1)
SHARES	6. SHARED VOTING POWER	0
BENEFICIALLY	7. SOLE DISPOSITIVE POWER	2,162,870 (1)
OWNED BY SUCH	8. SHARED DISPOSITIVE POWER	0
REPORTING		
PERSON WITH:		

9. Aggregate Amount Beneficially Owned by Such Reporting Person

2,162,870 (1)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

5.7%

12. Type of Reporting Person (See Instructions)

IN

(1) Includes: (i) 72,300 shares held in an account for which Mr. Solit is a trustee; and (ii) 182,833 shares held in accounts in the name of Mr. Solit's spouse and children.

* Ownership information above is as of the close of business on July 16, 2019, the business day before the filing date of this Schedule 13G.

1. Name of Reporting Person

Potomac Capital Management Inc.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

New York

NUMBER OF	5. SOLE VOTING POWER	1,907,737
SHARES	6. SHARED VOTING POWER	0
BENEFICIALLY	7. SOLE DISPOSITIVE POWER	1,907,737
OWNED BY SUCH	8. SHARED DISPOSITIVE POWER	0
REPORTING		
PERSON WITH:		

9. Aggregate Amount Beneficially Owned by Such Reporting Person

1,907,737

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

5.1%

12. Type of Reporting Person (See Instructions)

CO

* Ownership information above is as of the close of business on July 16, 2019, the business day before the filing date of this Schedule 13G.

1. Name of Reporting Person

Potomac Capital Management V LLC

2. Check the Appropriate Box if a Member of a Group (See Instructions)

- (a)
- (b)

3. SEC Use Only

4. Citizenship or Place of Organization

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY SUCH REPORTING PERSON WITH:	5. SOLE VOTING POWER	1,907,737
	6. SHARED VOTING POWER	0
	7. SOLE DISPOSITIVE POWER	1,907,737
	8. SHARED DISPOSITIVE POWER	0

9. Aggregate Amount Beneficially Owned by Such Reporting Person

1,907,737

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

5.1%

12. Type of Reporting Person (See Instructions)

OO

* Ownership information above is as of the close of business on July 16, 2019, the business day before the filing date of this Schedule 13G.

1. Name of Reporting Person

Potomac Capital Partners V, LP

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of Organization

Delaware

NUMBER OF	5. SOLE VOTING POWER	1,907,737
SHARES	6. SHARED VOTING POWER	0
BENEFICIALLY	7. SOLE DISPOSITIVE POWER	1,907,737
OWNED BY SUCH	8. SHARED DISPOSITIVE POWER	0
REPORTING		
PERSON WITH:		

9. Aggregate Amount Beneficially Owned by Such Reporting Person

1,907,737

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

5.1%

12. Type of Reporting Person (See Instructions)

PN

* Ownership information above is as of the close of business on July 16, 2019, the business day before the filing date of this Schedule 13G.

Item 1.

- (a) The name of the issuer is Harvard Bioscience, Inc. (the “*Issuer*”).
- (b) The principal executive offices of the Issuer are located at 84 October Hill Road, Holliston, MA 01746.

Item 2.

- (a) This statement (this “*Statement*”) is being filed by: (1) Paul J. Solit; (2) Potomac Capital Management Inc., a New York corporation (the “*Investment Manager*”); (3) Potomac Capital Management V LLC, a Delaware limited liability company (the “*General Partner*”); and (4) Potomac Capital Partners V, LP, a Delaware limited partnership (the “*Fund*”) (all of the foregoing, collectively, the “*Reporting Persons*”). The Fund is a private investment vehicle. The Investment Manager is the investment manager of the Fund. The General Partner is the general partner of the Fund. Mr. Solit is the principal and controlling person of the Investment Manager and the General Partner. Mr. Solit directly beneficially owns 255,133 shares of Common Stock (as defined below) reported in this Statement. The Fund directly owns 1,907,737 shares of Common Stock reported in this Statement. Mr. Solit, the Investment Manager and the General Partner may be deemed to beneficially own the shares of Common Stock owned directly by the Fund. Each Reporting Person disclaims beneficial ownership with respect to any shares other than the shares beneficially owned directly by such Reporting Person.
- (b) The principal business office of the Reporting Persons is 150 East 52nd Street, 3rd Floor, New York, NY 10022.
- (c) For citizenship information see Item 4 of the cover page of each Reporting Person.
- (d) This Statement relates to the Common Stock, par value \$0.01 per share, of the Issuer (the “*Common Stock*”).
- (e) The CUSIP Number of the Common Stock is 416906105.

Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

- (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: _____

Item 4. Ownership.

See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on July 16, 2019, the business day before the date of filing of this Schedule 13G.

As of the Event Date of July 9, 2019, the Reporting Persons collectively beneficially owned 2,048,389 shares of Common Stock, representing 5.4% of all of the outstanding shares of Common Stock.

The percentages of beneficial ownership contained herein are based on 37,687,608 shares of Common Stock outstanding as of May 2, 2019, as reported by the Issuer in its Form 10-Q filed on May 8, 2019.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

- (a) Not applicable.
- (b) Not applicable.
- (c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

EXHIBIT INDEX

Exhibit No.

Document

1 Joint Filing Agreement

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value \$0.01 per share, of Harvard Bioscience, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby execute this Agreement.

Dated: July 17, 2019

Paul J. Solit
Potomac Capital Management Inc.
Potomac Capital Management V LLC
Potomac Capital Partners V, LP

By: /s/ Paul J. Solit
Paul J. Solit, for himself, as
President of the Investment
Manager and as the Managing
Member of the General Partner (for
itself and on behalf of the Fund)
